Am. J. Respir. Crit. Care Med., Volume 159, Number 4, April 1999, 1342-1350

Angiotensin-1 Converting Enzyme Polymorphisms in Chronic Beryllium Disease

LISA A. MAIER, MARY V. RAYNOLDS, DAVID A. YOUNG, ELIZABETH A. BARKER, and LEE S. NEWMAN

Department of Medicine, National Jewish Medical and Research Center, Denver; Departments of Medicine, Cellular and Structural Biology, and Preventive Medicine and Biometrics, University of Colorado Health Sciences Center, Denver, Colorado

To test the hypothesis that the angiotensin converting enzyme (ACE) genotype is associated with chronic beryllium disease (CBD) and disease severity, we studied 50 cases of CBD and compared their ACE genotype to that of two different control groups, consisting of: (1) 50 participants from a beryllium machining facility; and (2) 50 participants from a non-beryllium-associated workplace. We found no statistically significant difference in the frequency of the I or D allele or of the DD genotype among cases of CBD and either control group. The odds ratio (OR) for the CBD DD genotype as compared with the non-DD genotype was 1.58 (95% confidence interval [CI]: 0.68 to 3.66, p = 0.12) for the beryllium-exposed control group, and 1.09 (95% CI: 0.48 to 2.46, p = 0.56) for the non-beryllium-exposed controls. We found an association between serum ACE activity and the ACE genotype, with DD cases having the highest median serum ACE activity (p = 0.005). We evaluated the beryllium lymphocyte proliferation test (BeLPT), bronchoalveolar lavage (BAL) cell components, chest radiography, pulmonary function test results, and exercise physiology in our CBD cases. No statistically significant associations with these disease markers were found for the CBD cases with the DD genotype. Although the difference was not statistically significant, the DD cases had a shorter median duration of exposure to beryllium before diagnosis of CBD, and tended to have a weaker response in their blood and BAL BeLPT than did the non-DD cases. These findings may indicate that the ACE genotype is important in the immune response to beryllium and in progression to beryllium disease.

This article has been cited by other articles:

				D C Christiani, A J Mehta, and C-L Yu Genetic susceptibility to occupational exposures Occup. Environ. Med., June 1, 2008; 65(6): 430 - 436. [Abstract] [Full Text] [PDF]

				A. C. Jonth, L. Silveira, T. E. Fingerlin, H. Sato, J. C. Luby, K. I. Welsh, C. S. Rose, L. S. Newman, R. M. du Bois, L. A. Maier, et al. TGF-beta1 Variants in Chronic Beryllium Disease and Sarcoidosis J. Immunol., September 15, 2007; 179(6): 4255 - 4262. [Abstract] [Full Text] [PDF]

				M. Adamzik, U. Frey, S. Sixt, L. Knemeyer, M. Beiderlinden, J. Peters, and W. Siffert ACE I/D but not AGT (-6)A/G polymorphism is a risk factor for mortality in ARDS Eur. Respir. J., March 1, 2007; 29(3): 482 - 488. [Abstract] [Full Text] [PDF]

				L. A. Maier, D. S. McGrath, H. Sato, P. Lympany, K. Welsh, R. du Bois, L. Silveira, A. P. Fontenot, R. T. Sawyer, E. Wilcox, et al. Influence of MHC CLASS II in Susceptibility to Beryllium Sensitization and Chronic Beryllium Disease J. Immunol., December 15, 2003; 171(12): 6910 - 6918. [Abstract] [Full Text] [PDF]

				R. P. Marshall, S. Webb, G. J. Bellingan, H. E. Montgomery, B. Chaudhari, R. J. McAnulty, S. E. Humphries, M. R. Hill, and G. J. Laurent Angiotensin Converting Enzyme Insertion/Deletion Polymorphism Is Associated with Susceptibility and Outcome in Acute Respiratory Distress Syndrome Am. J. Respir. Crit. Care Med., September 1, 2002; 166(5): 646 - 650. [Abstract] [Full Text] [PDF]

				L. A. MAIER, R. T. SAWYER, R. A. BAUER, L. A. KITTLE, P. LYMPANY, D. MCGRATH, R. DUBOIS, E. DANILOFF, C. S. ROSE, and L. S. NEWMAN High Beryllium-stimulated TNF-alpha Is Associated with the -308 TNF-alpha Promoter Polymorphism and with Clinical Severity in Chronic Beryllium Disease Am. J. Respir. Crit. Care Med., October 1, 2001; 164(7): 1192 - 1199. [Abstract] [Full Text] [PDF]